Growth Of Drug-Device Combination Products Impacting The Way Drugs Are Developed
Recognizing the growing impact of combination products, the U.S. FDA established a new organizational entity in December of 2002 to coordinate the regulatory process for the rising number of applications comprised of two or more regulated components. The integration of drug and delivery device results in a synergistic merging in which therapeutic benefit is increased and outcomes are improved.
The growth of combination products is having a significant effect on the way drugs and devices are developed. Cooperation between device designers and drug developers is occurring much earlier in the drug development cycle, allowing device designs in many cases to be tailored to the bioavailability targets and pharmacokinetic profiles of specific drug therapies. The new devices are patient-friendly, easing compliance concerns, which have a non-negligible effect on drug formulations and delivery decisions, and are a significant factor in the prescribing decisions of most physicians.
More information is available here.
About Greystone
Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology and market assessment.
Greystone Associates
Creºtere a consumului de droguri-Aparat Combinaþie Produse impact Calea Drogurile sunt dezvoltate - Growth Of Drug-Device Combination Products Impacting The Way Drugs Are Developed - articole medicale engleza - startsanatate